Member Description Overlay
Leerink People

At LEERINK, we share a common desire to achieve the highest level of success for our clients. We pride ourselves on being the most focused and passionate healthcare investment banking professionals. We leverage our combined knowledge and experience to empower our clients to make well-informed strategic decisions that create opportunity and shareholder value while paving the way for the innovations that improve human health.

Jeffrey A. Leerink

Chairman and Chief Executive Officer

close

Jeffrey A. Leerink

Chairman and Chief Executive Officer

Jeffrey A. Leerink is Chairman and Chief Executive Officer of LEERINK Partners, a healthcare investment bank that helps advance healthcare innovations that improve the global healthcare system.

Mr. Leerink founded the firm in 1995 and under his leadership, LEERINK has grown to become a leading healthcare investment bank and company building partner. The firm is focused on providing differentiated healthcare knowledge and equity capital markets, equity research and mergers and acquisitions expertise to help its clients define and achieve their strategic and capital markets objectives. In 2008, Mr. Leerink co-founded and was a member of the Board of Directors of Humedica, Inc., a clinical intelligence company that was incubated at LEERINK. In 2013 the company was acquired by Optum, a subsidiary of UnitedHealth Group. Leerink Capital Partners (“LCP”), the asset management affiliate of LEERINK Partners, was formed in 2013 to build and lead a multi-strategy, healthcare-focused principal investment business with a dedicated team experienced in originated, structuring and managing healthcare investments. 

Currently, Mr. Leerink is a member of the Harvard Medical School Board of Fellows and is a member of the New England Chapter of CEO’s Against Cancer serving as Vice Chair. He is also a Board member at Big Brother Big Sister of Massachusetts Bay. From 2013 – 16, Mr. Leerink served as Chairman of the Board at Big Brother Big Sisters of Massachusetts Bay. Additionally, Mr. Leerink serves as a Board member at FogPharma.

Mr. Leerink holds a B.A. in Economics from Union College.

 

Jim Boylan

President, Head of Investment Banking

close

Jim Boylan

President, Head of Investment Banking

James (Jim) Boylan is the President of LEERINK Partners and the Head of Investment Banking, having joined the firm in 2009. Mr. Boylan has 20+ years of experience in healthcare investment banking.

Prior to joining LEERINK, Mr. Boylan was at Merrill Lynch & Co. for 12 years where he was a Managing Director in the healthcare group from 2005-2009 and a Managing Director in the Mergers & Acquisitions department from 1997-2004.

Mr. Boylan earned his MBA from Columbia University in 1994 and a B.S. from Lehigh University in 1989.

Joseph Gentile

Chief Administrative Officer

close

Joseph Gentile

Chief Administrative Officer

Joseph Gentile joined Leerink Partners in 2007 as Chief Administrative Officer. Mr. Gentile was formerly CFO, Global Investment Bank at Lehman Brothers, where he directed the accounting and financial needs within the Fixed Income division, the largest operating division of Lehman Brothers.

Prior to that, he served as CFO of the Global Corporate and Investment Bank at Bank of America, where he led the Capital Markets Division. Previously, Mr. Gentile spent more than 10 years with J.P. Morgan in various financial management positions, including Global Head of Financial Risk Management. He holds a B.S. in accounting and MBA in finance from St. John’s University.

Dan Dubin, M.D.

Vice Chairman; Founder of MEDACorp

close

Dan Dubin, M.D.

Vice Chairman; Founder of MEDACorp

Dr. Dubin has advised life sciences companies and investors for nearly 20 years and has executed over 100 financing, partnership, and M&A transactions for clients. He leads LEERINK Partners’ dermatology and medical aesthetics advisory practice which serves both emerging growth and Fortune 100 companies. He also specializes in executing private placements with crossover investors and Form 10 alternative go-public transactions.

In 1996, he founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He serves as a director of Living Proof and an advisor to SKS Ocular. He has also served as Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Tim Gerhold

General Counsel

close

Tim Gerhold

General Counsel

Timothy Gerhold joined LEERINK Partners in 2006 as its General Counsel and Senior Managing Director of the Compliance and Legal Group.

Prior to joining LEERINK, Mr. Gerhold was the General Counsel and Head of Compliance of BancBoston Capital, one of the largest bank-affiliated private equity groups in the United States. Before that, Mr. Gerhold held a number of positions in the Law Office of BankBoston Financial Corporation, including Group Head of the Capital Markets Group and Group Head of the Financial Services Group.

Previously, Mr. Gerhold practiced law at Goodwin Proctor LLP. Mr. Gerhold received his B.A. from Carleton College, and his J.D. from Yale Law School.

Robert Leerink

Senior Managing Director, Head of Institutional Equities

close

Robert Leerink

Senior Managing Director, Head of Institutional Equities

Robert Leerink has been with Leerink Partners since its inception in 1995. He is a Senior Managing Director of Leerink’s Institutional Sales team.

Prior to joining Institutional Sales in 2000, Mr. Leerink led the Private Client Services group at Leerink. He began his career in the private client services division of Fechtor Detwiler.

Mr. Leerink holds a bachelor’s degree from Babson College.

Check the background of this investment professional on FINRA’s BrokerCheck.

Maura Polak

Managing Director, Human Resources

close

Maura Polak

Managing Director, Human Resources

Maura Polak has led LEERINK Partners Human Resources since 2010, including all recruiting, employee relations, compensation and benefits initiatives. Ms. Polak has 15 years of experience in Human Resources. She joined the Firm in 2004 as a Human Resources Associate and prior to that, she was a Human Resources Representative at Peer Review Analysis, a Division of Fortis, Inc., where she managed through a series of mergers, acquisitions and a divestiture.

She holds a BA in both Psychology and Spanish from Providence College.

John L. Sullivan, CFA

Senior Managing Director, Equity Research; Healthcare Strategist

close

John L. Sullivan, CFA

Senior Managing Director, Equity Research; Healthcare Strategist

John L. Sullivan is Senior Managing Director of Equity Research at LEERINK Partners and its Healthcare Investment Strategist. As a sector analyst, Mr. Sullivan ranked #3 in The Wall Street Journal’s 2008 “Best on the Street” analysts’ survey. As a stock picker in 2007, he earned a #2 ranking among the life sciences tools and services analysts ranked by StarMine in Forbes.com and a #3 ranking among the same group for accuracy of his earnings estimates.

Previously, Mr. Sullivan was a Vice President, Senior Equity Research Analyst at Stephens Inc. where his primary focus was on companies possessing enabling technologies for health care-related products for research and drug discovery. Mr. Sullivan, a Chartered Financial Analyst, received his Bachelor of Science degree from Boston University and an MBA from J.L. Kellogg Graduate School of Management at Northwestern University.

David Redlick

Special Advisor

close

David Redlick

Special Advisor

David Redlick is a special advisor at LEERINK Partners. He recently retired from WilmerHale, where he practiced law for over 40 years. Mr. Redlick’s practice focused on corporate and securities law, with an emphasis on public offerings, mergers and acquisitions, venture capital transactions and corporate collaborations. Mr. Redlick served as counsel for a broad range of clients, including public and private life sciences and high technology companies, investment banks and venture capital funds. For many years, Mr. Redlick was rated by Chambers USA and Chambers Global in Band 1 in the Life Sciences: Corporate/Commercial category and as a “Leading Lawyer” in life sciences by Legal 500 United States. Mr. Redlick was recently included in the Chambers shortlist for selection of the 100 top business lawyers in the United States. He received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.